165 related articles for article (PubMed ID: 36230603)
1. Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive and Drug-Resistant Bladder Cancer Cell Lines In Vitro.
Xie H; Rutz J; Maxeiner S; Grein T; Thomas A; Juengel E; Chun FK; Cinatl J; Haferkamp A; Tsaur I; Blaheta RA
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230603
[TBL] [Abstract][Full Text] [Related]
2. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
[TBL] [Abstract][Full Text] [Related]
3. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
[TBL] [Abstract][Full Text] [Related]
4. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.
Juengel E; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Tsaur I; Nelson K; Bechstein WO; Haferkamp A; Blaheta RA
Oncotarget; 2016 Dec; 7(51):85208-85219. PubMed ID: 27863441
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7.
Rutz J; Thaler S; Maxeiner S; Chun FK; Blaheta RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218199
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane as an adjunctive to everolimus counteracts everolimus resistance in renal cancer cell lines.
Juengel E; Euler S; Maxeiner S; Rutz J; Justin S; Roos F; Khoder W; Nelson K; Bechstein WO; Blaheta RA
Phytomedicine; 2017 Apr; 27():1-7. PubMed ID: 28314474
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
Juengel E; Najafi R; Rutz J; Maxeiner S; Makarevic J; Roos F; Tsaur I; Haferkamp A; Blaheta RA
Oncotarget; 2017 Dec; 8(66):110016-110028. PubMed ID: 29299126
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane-cisplatin combination inhibits the stemness and metastatic potential of TNBCs via down regulation of sirtuins-mediated EMT signaling axis.
Sinha S; Sharma S; Sharma A; Vora J; Shrivastava N
Phytomedicine; 2021 Apr; 84():153492. PubMed ID: 33640782
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
Islam SS; Mokhtari RB; Akbari P; Hatina J; Yeger H; Farhat WA
Target Oncol; 2016 Apr; 11(2):209-27. PubMed ID: 26453055
[TBL] [Abstract][Full Text] [Related]
12. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.
Chen H; Landen CN; Li Y; Alvarez RD; Tollefsbol TO
Exp Cell Res; 2013 Mar; 319(5):697-706. PubMed ID: 23333498
[TBL] [Abstract][Full Text] [Related]
13. The Antitumor Effect of Curcumin in Urothelial Cancer Cells Is Enhanced by Light Exposure In Vitro.
Roos F; Binder K; Rutz J; Maxeiner S; Bernd A; Kippenberger S; Zöller N; Chun FK; Juengel E; Blaheta RA
Evid Based Complement Alternat Med; 2019; 2019():6374940. PubMed ID: 30984278
[TBL] [Abstract][Full Text] [Related]
14. Bladder Cancer Metastasis Induced by Chronic Everolimus Application Can Be Counteracted by Sulforaphane In Vitro.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759798
[TBL] [Abstract][Full Text] [Related]
15. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction.
Zhao F; Vakhrusheva O; Markowitsch SD; Slade KS; Tsaur I; Cinatl J; Michaelis M; Efferth T; Haferkamp A; Juengel E
Cells; 2020 Dec; 9(12):. PubMed ID: 33316936
[TBL] [Abstract][Full Text] [Related]
16. Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation.
Juengel E; Rutz J; Meiborg M; Markowitsch SD; Maxeiner S; Grein T; Thomas A; Chun FK; Haferkamp A; Tsaur I; Vakhrusheva O; Blaheta RA
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835543
[TBL] [Abstract][Full Text] [Related]
17. Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention.
Wang L; Liu D; Ahmed T; Chung FL; Conaway C; Chiao JW
Int J Oncol; 2004 Jan; 24(1):187-92. PubMed ID: 14654956
[TBL] [Abstract][Full Text] [Related]
18. Concomitant Use of Sulforaphane Enhances Antitumor Efficacy of Sunitinib in Renal Cell Carcinoma In Vitro.
Tsaur I; Thomas A; Taskiran E; Rutz J; Chun FK; Haferkamp A; Juengel E; Blaheta RA
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230567
[TBL] [Abstract][Full Text] [Related]
19. The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation.
He C; Buongiorno LP; Wang W; Tang JCY; Miceli N; Taviano MF; Shan Y; Bao Y
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443505
[TBL] [Abstract][Full Text] [Related]
20. The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.
Abbaoui B; Telu KH; Lucas CR; Thomas-Ahner JM; Schwartz SJ; Clinton SK; Freitas MA; Mortazavi A
J Proteomics; 2017 Mar; 156():94-103. PubMed ID: 28132875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
